PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
EBIT growth 50-75% of TRAW's 10.64%. Martin Whitman would suspect suboptimal resource allocation.
7.72%
Operating income growth at 50-75% of TRAW's 10.64%. Martin Whitman would doubt the firm’s ability to compete efficiently.
12.50%
Net income growth under 50% of TRAW's 69.02%. Michael Burry would suspect the firm is falling well behind a key competitor.
15.94%
EPS growth under 50% of TRAW's 76.69%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
15.94%
Diluted EPS growth under 50% of TRAW's 76.69%. Michael Burry would worry about an eroding competitive position or excessive dilution.
4.10%
Share reduction more than 1.5x TRAW's 32.90%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
4.10%
Diluted share reduction more than 1.5x TRAW's 32.90%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Negative OCF growth while TRAW is at 5.99%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-32.79%
Negative FCF growth while TRAW is at 5.99%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Negative 10Y OCF/share CAGR while TRAW stands at 84.14%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-29341.33%
Negative 5Y OCF/share CAGR while TRAW is at 84.14%. Joel Greenblatt would question the firm’s operational model or cost structure.
-23.11%
Negative 3Y OCF/share CAGR while TRAW stands at 90.23%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-39968.68%
Negative 10Y net income/share CAGR while TRAW is at 94.02%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-32.05%
Negative 5Y net income/share CAGR while TRAW is 94.02%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-188.96%
Negative 3Y CAGR while TRAW is 96.29%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
7755.72%
Equity/share CAGR of 7755.72% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2687.68%
Equity/share CAGR of 2687.68% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-9.18%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.82%
We have a declining book value while TRAW shows 112.27%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-14.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.